The Wistar Institute provides an AAALAC-accredited Animal Facility that serves faculty from the Gene Expression and Regulation, Oncogenesis, and Immunology Cancer Center programs. The facility is maintained as a modified barrier Biosafety Level 2 (BSL2) facility by highly qualified and experienced personnel. In addition to ordering and housing research animals, the facility houses the Mouse Genetics Facility. The Animal Facility supports the severe combined immunodeficiency (SCID) mouse breeding colony, quarantine housing, technical training, Intravital Imaging System (MS) 200i in vivo imaging capabilities, animal health surveillance, veterinary coverage, new employee hands-on training, and Institutional Animal Care and Use Committee (IACUC) testing. Since 2003, The Wistar Institute has invested over $1 million into the Animal Facility for structural upgrades and new equipment supporting Cancer Center programs. A new polishing chiller augments chilled water supplies for cooling, and ensures stable temperature regulation for the Facility during the hottest weather, as well as back-up chilled water supplies in the event of failure in the primary cooling system. Additional upgrades to the facility infrastructure include improved ventilation, security, and emergency capabilities. Direct Digital Control monitoring has been incorporated into all animal rooms, offering 24-hour monitoring of the temperature as well as the heating, ventilation, and air condition (HVAC) system. Research infrastructure improvements include the addition of an IVIS imager, permitting tumor growth monitoring over time at high resolution;new state-of-the-art biocontainment equipment for expanding studies involving viral vectors and other infectious agents;and a transgenic mouse suite for use by the expanding Mouse Genetics Shared Facility. Future goals reflect the needs of cancer researchers and shared facilities and include the purchase of additional bio-containment caging equipment and Class II bio-safety cabinets;an anesthesia machine;a stereomicroscope for mouse surgical procedures;and continued upgrades to security systems.

Public Health Relevance

Animal models of human cancer have become irreplaceable tools to study how cancer behaves in the context of development, microenvironment, immunology, angiogenesis, progression, invasion and metastasis. These studies are only valid if the animals are cared for in a controlled, humane environment. The Animal Facility is run by a very professional staff that ensures these principles.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA010815-43
Application #
8378481
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-03-01
Budget End
2013-02-28
Support Year
43
Fiscal Year
2012
Total Cost
$242,649
Indirect Cost
$104,256
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Hu, Xiaowen; Sood, Anil K; Dang, Chi V et al. (2018) The role of long noncoding RNAs in cancer: the dark matter matters. Curr Opin Genet Dev 48:8-15
Saglam, Ozlen; Conejo-Garcia, Jose (2018) PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer. Integr Cancer Sci Ther 5:
Liu, Shujing; Zhang, Gao; Guo, Jianping et al. (2018) Loss of Phd2 cooperates with BRAFV600E to drive melanomagenesis. Nat Commun 9:5426
Duperret, Elizabeth K; Trautz, Aspen; Stoltz, Regina et al. (2018) Synthetic DNA-Encoded Monoclonal Antibody Delivery of Anti-CTLA-4 Antibodies Induces Tumor Shrinkage In Vivo. Cancer Res 78:6363-6370
Papasavvas, Emmanouil; Lada, Steven M; Joseph, Jocelin et al. (2018) Analytical ART interruption does not irreversibly change pre-interruption levels of cellular HIV. AIDS :
Kugel 3rd, Curtis H; Douglass, Stephen M; Webster, Marie R et al. (2018) Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clin Cancer Res 24:5347-5356
Reyes-Uribe, Patricia; Adrianzen-Ruesta, Maria Paz; Deng, Zhong et al. (2018) Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma. Oncogene 37:4058-4072
Bhattacharjee, Souvik; Coppens, Isabelle; Mbengue, Alassane et al. (2018) Remodeling of the malaria parasite and host human red cell by vesicle amplification that induces artemisinin resistance. Blood 131:1234-1247
Fukumoto, Takeshi; Park, Pyoung Hwa; Wu, Shuai et al. (2018) Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. Cell Rep 22:3393-3400
Thangavel, Chellappagounder; Boopathi, Ettickan; Liu, Yi et al. (2018) Therapeutic Challenge with a CDK 4/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Non-Small Cell Lung Cancer. Clin Cancer Res 24:1402-1414

Showing the most recent 10 out of 741 publications